Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB me...
79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic br...
Collaboration with MSK's Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of t...
Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3...
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...
HC Wainwright & Co. analyst Emily Bodnar maintains BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and raises the price t...
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...
